aTYR PHARMA INCATYREarnings & Financial Report
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
ATYR Q3 2025 Key Financial Metrics
Revenue
$190.0K
Gross Profit
N/A
Operating Profit
$-26.7M
Net Profit
$-25.7M
Gross Margin
N/A
Operating Margin
-14076.3%
Net Margin
-13549.5%
YoY Growth
N/A
EPS
$-0.26
Financial Flow
aTYR PHARMA INC Q3 2025 Financial Summary
aTYR PHARMA INC reported revenue of $190.0K for Q3 2025, with a net profit of $-25.7M (-13549.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $190.0K |
|---|---|
| Net Profit | $-25.7M |
| Gross Margin | N/A |
| Operating Margin | -14076.3% |
| Report Period | Q3 2025 |
aTYR PHARMA INC Annual Revenue by Year
aTYR PHARMA INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $235.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $235.0K |
| 2023 | $353.0K |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $235000 | $0 | $0 | $0 | $0 | $0 | $190000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $120.7M | $113.3M | $105.9M | $91.6M | $96.8M | $97.2M | $101.5M | $106.7M |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $90.7M | $84.5M | $81.6M | $65.3M | $70.0M | $75.0M | $74.8M | $80.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-11.1M | $-22.4M | $-20.4M | $-13.2M | $-13.1M | $-15.4M | $-13.9M | $-20.5M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M